Trial · NCT00345371
Topiramate for the Treatment of Methamphetamine Dependence - 1
NCT00345371, Phase 2, Completed, National Institute on Drug Abuse (NIDA); results first posted 2017-02-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topiramate for the Treatment of Methamphetamine Dependence - 1. Trials, record NCT00345371. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00345371
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topiramate for the Treatment of Methamphetamine Dependence - 1
- NCT number
- NCT00345371
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 140 participants, actual
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- Conditions
- Methamphetamine
- Interventions
- Topiramate, Placebo Oral Tablet
- First posted
- 2006-06-28
- Last updated
- 2017-03-27
- Results first posted
- 2017-02-23
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Abstinence (Weeks 6 - 12) | weeks 6 through 12 | The number of participants who abstained from methamphetamine from weeks 6 through 12 |
| Secondary | Abstinence (Weeks 1 - 12) | Weeks 1 through 12 | Number of participants who abstained from methamphetamine from weeks 1 through 12 |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Abstinence (Weeks 6 - 12) | weeks 6 through 12 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Abstinence (Weeks 1 - 12) | Weeks 1 through 12 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Abstinence (Weeks 6 - 12) | Topiramate | Week 6 | 49 | Participants | |
| Abstinence (Weeks 6 - 12) | Placebo Oral Tablet | Week 6 | 49 | Participants | |
| Abstinence (Weeks 6 - 12) | Topiramate | Week 7 | 43 | Participants | |
| Abstinence (Weeks 6 - 12) | Placebo Oral Tablet | Week 7 | 48 | Participants | |
| Abstinence (Weeks 6 - 12) | Topiramate | Week 8 | 46 | Participants | |
| Abstinence (Weeks 6 - 12) | Placebo Oral Tablet | Week 8 | 45 | Participants | |
| Abstinence (Weeks 6 - 12) | Topiramate | Week 9 | 40 | Participants | |
| Abstinence (Weeks 6 - 12) | Placebo Oral Tablet | Week 9 | 41 | Participants | |
| Abstinence (Weeks 6 - 12) | Topiramate | Week 10 | 38 | Participants | |
| Abstinence (Weeks 6 - 12) | Placebo Oral Tablet | Week 10 | 33 | Participants |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Topiramate | 69 | |
| Overall Study | STARTED | Placebo Oral Tablet | 71 | |
| Overall Study | COMPLETED | Topiramate | 39 | |
| Overall Study | COMPLETED | Placebo Oral Tablet | 38 | |
| Overall Study | NOT COMPLETED | Topiramate | 30 | |
| Overall Study | NOT COMPLETED | Placebo Oral Tablet | 33 |
Source ClinicalTrials.gov
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Topiramate | 33 | 69 | 76 |
| other | Headache | Nervous system disorders | Placebo Oral Tablet | 30 | 71 | 68 |
| other | Fatigue | General disorders | Topiramate | 20 | 69 | 22 |
| other | Fatigue | General disorders | Placebo Oral Tablet | 14 | 71 | 17 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Topiramate | 16 | 69 | 18 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo Oral Tablet | 11 | 71 | 14 |
| other | Diarrhea | Gastrointestinal disorders | Topiramate | 11 | 69 | 14 |
| other | Diarrhea | Gastrointestinal disorders | Placebo Oral Tablet | 8 | 71 | 12 |
| other | Dizziness | Nervous system disorders | Topiramate | 9 | 69 | 10 |
| other | Dizziness | Nervous system disorders | Placebo Oral Tablet | 5 | 71 | 8 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Topiramate | ||
| Total, all-cause mortality | Placebo Oral Tablet | ||
| Total, other adverse events | Topiramate | 63 | 69 |
| Total, other adverse events | Placebo Oral Tablet | 64 | 71 |
| Total, serious adverse events | Topiramate | 3 | 69 |
| Total, serious adverse events | Placebo Oral Tablet | 8 | 71 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Topiramate vs Placebo Oral Tablet: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00345371
GET https://conductscience.org/api/trials/v1/NCT00345371/results?page=2